Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.56 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10160948 | 1.00 | EGFR (0.56) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL13622708 | 0.93 | EGFR (0.56) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL10160950 | 0.92 | EGFR (0.53) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL428513 | 0.92 | EGFR (0.53) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL10160951 | 0.90 | EGFR (0.54) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL426640 | 0.90 | EGFR (0.54) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL4121881 | 0.90 | BRAF (0.67) | EGFRKDRBRAFFLT3ROCK2 | |
| SCHEMBL426005 | 0.90 | EGFR (0.57) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL458720 | 0.90 | EGFR (0.57) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL425676 | 0.86 | EGFR (0.48) | EGFRKDRBRAFEHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687002-A4 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2008-07-23 | — | — | EP | claimed |
| JP-2007510745-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | claimed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1687002-A4 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |